Open Source Stem Cell R&D (fwd)
Hi,
I did not really found a download or a license but if there is any interest
someone might do a more detailed research on the home page
http://usbiodefense.com/news_012105.php
which seams responsible for the message on LinuxMedNews:
http://linuxmednews.com/linuxmednews/1106324091/index_html
U.S. BioDefense to Launch Open Source Platform for Rapid Stem Cell Research and
Development. Read on for the complete announcement.
City of Industry, CA January 21, 2005 - U.S. BioDefense, Inc. (OTCBB: UBDF)
announced today that it is developing an Open Source Stem Cell Research
Platform to leverage the distributed power of open source development. The Open
Source Stem Cell Research Platform will allow researchers at Universities,
Government Agencies, and Fortune 500 companies to read, distribute, modify and
contribute to stem cell and biotechnology research in an efficient and
streamlined method. The platform which can be used as an Intranet or online
will provide access to bioinformatic tools and serve as a robust utility for
the rapid evolution of Stem Cell technology research, development, and
commercialization.
U.S. BioDefense CEO David Chin stated, We intend to quickly scale up revenues
by focusing on selling Open Source collaborative technology research and
transfer tools as well as commercializing leading edge technology. The
proliferation of open source development to industries beyond software has
prompted U.S. BioDefense to aggressively lead the drive in implementing the
philosophy and benefits to the emerging stem cell industry. We are positioning
ourselves at the nucleus of Stem Cell research and development tools in order
to leverage the potential of California's $3 Billion Stem Cell Research Fund
and our Department of Defense SBIR Grant response related to Embryonic Stem
Cell technology for Bioengineered skin commercialization.
U.S. BioDefense is aggressively pursuing its technology transfer initiative by
incorporating the distributed power of open source development in individual
biotechnology fields related to biodefense research beginning with its Stem
Cell commercialization initiative. The Open Source Stem Cell Research Platform
being developed by U.S. BioDefense is an adaptation of the monumental open
source movement in software development that has also been embraced by large
technology companies like IBM (NYSE: IBM), Novell and Sun Microsystems (Nasdaq:
SUNW).
According to Wired Magazine recently the idea of open source biotechnology has
been gaining momentum with the introduction of BIOS, the Biological Innovation
for Open Society (www.bios.net), a non profit with the support of The
Rockefeller Foundation encompassing the creative use of living systems and
their environment, and with the implementation of open source principles and
development methods in the field of bioinformatics. According to BIOS web site
the organization will create a mechanism BioForge by which like-minded
individuals and agencies can collaborate with optimum effectiveness to solve
problems and create technologies under an open-access regime. The goal of
BioForge is to forge a dynamic protected commons of enabling technologies that
will be available to the worldwide inventive community for use in improvement
and new innovations. The VA Software SourceForge.net Open Source network
provides a scalable solution for empowering development teams across the
diverse worldwide Open Source community. Today, SourceForge.net is the world's
largest Open Source software development web site, hosting more than 90,000
projects and over 950,000 registered users. OSTG receives more than 230 million
page views and over 16 million unique visitors every single month.
About U.S. BioDefense, Inc.
U.S. BioDefense is a Department of Defense central contractor that researches,
develops, and commercializes leading-edge biotechnology. U.S. BioDefense
recently announced that it had filed its Small Business Innovation Research
(SBIR) Grant proposal Number C051-117-0060 with the Department of Defense
Chemical Biological Defense Agency in response to SBIR (dodsbir.net) Topic
number CBD05-117 'Stem Cell Technology And Autologous Bioengineered Skin For
The Treatment of Cutaneous Vesicant Injury'. U.S. BioDefense recently sponsored
the Project T2 Technology Transfer Conference, the nation's leading showcase of
new university technologies, being hosted at the Wilshire Grand Hotel in Los
Angeles, CA. Other sponsors (http://www.projectt2.org/sponsors.htm) include
Southern California Edison, Latham & Watkins, Morrison & Foerster,
PricewaterhouseCoopers, Canadian Consulate General, and Genzyme (NYSE: GENZ).
U.S. BioDefense, Inc. recently entered into a Commercial Evaluation License
Agreement with the National Institutes of Health (NIH). The biotechnology is
related to a method for universal inactivation of viruses, parasites and tumor
cells. These inactivated agents can be used as vaccines against the diseases
caused by such viruses, parasites and tumor cells. Hence, the immunogenic of
the agent as a whole is maintained and can be safely used for vaccination
without the threat of infection. U.S. BioDefense, Inc. intends to conduct
laboratory experiments under this Agreement to evaluate the suitability for
commercial development. Furthermore, U.S. BioDefense, Inc. has agreed to
provide the facilities, personnel, and expertise to evaluate the commercial
applications. NIH's bioterrorism budgets have jumped from $53 million in 2001
to $1.7 Billion in 2005.
Safe Harbor Statement Forward-Looking Statements Included in this release are
certain forward-looking'' statements, involving risks and uncertainties, which
are covered by the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including statements regarding the Company's financial
performance. Such statements are based on management's current expectations and
are subject to certain factors, risks and uncertainties that may cause actual
results, events and performance to differ materially from those referred to or
implied by such statements. In addition, actual future results may differ
materially from those anticipated, depending on a variety of factors, including
continued maintenance of favorable license arrangements, success of market
research identifying new product opportunities, successful introduction of new
products, continued product innovation, the success of enhancements to the
Company's brand image, sales and earnings growth, ability to attract and retain
key personnel, and general economic conditions affecting consumer spending,
including uncertainties relating to global political conditions, such as
terrorism. Information with respect to important factors that should be
considered is contained in the Company's Annual Report on Form 10-K as filed
with the Securities and Exchange Commission. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date hereof. The Company does not intend to update any of the forward-looking
statements after the date of this release to conform these statements to actual
results or to changes in its expectations, except as may be required by law.
CONTACT:
U.S. BioDefense, Inc.
David Chin, 626-961-0562
info@usbiodefense.com
< | Washington Monthly: The Best Care Anywhere >
Reply to: